{"nctId":"NCT00770510","briefTitle":"A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)","startDateStruct":{"date":"2008-09"},"conditions":["Primary Insomnia"],"count":192,"armGroups":[{"label":"Eszopiclone 1 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Eszopiclone 1 mg"]},{"label":"Eszopiclone 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Eszopiclone 2 mg"]},{"label":"Eszopiclone 3 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Eszopiclone 3 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Zolpidem Tartrate 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zolpidem Tartrate 10 mg"]}],"interventions":[{"name":"Eszopiclone 1 mg","otherNames":["SEP-190"]},{"name":"Eszopiclone 2 mg","otherNames":["SEP-190"]},{"name":"Eszopiclone 3 mg","otherNames":["SEP-190"]},{"name":"Placebo","otherNames":[]},{"name":"Zolpidem Tartrate 10 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants aged greater than or equal to 21 and less than 65 years at the time of obtaining written informed consent\n2. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version and have both of the following conditions which are persistent for more than or equal to 4 weeks before the start of observation period:\n\n   * Sleep latency of more than or equal to 30 minutes for more than or equal to 3 days a week\n   * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week\n3. Participants who meet both of the following based on polysomnogram (PSG) in observation period:\n\n   * Objective sleep latency of more than or equal to 20 minutes for 2 consecutive PSG days\n   * Objective total sleep time of less than or equal to 420 minutes for 2 consecutive PSG days, or objective wake time during sleep of more than or equal to 20 minutes for 2 consecutive PSG days\n\nExclusion Criteria:\n\n1. Participants with comorbid primary sleep disorders (e.g., circadian rhythm disorder, restless limb syndrome, periodic limb movement disorder, sleep apnea syndrome), other than primary insomnia.\n2. Participants with insomnia caused by pharmacological actions (drug-induced insomnia).\n3. Participants with comorbid sleep disorder associated with other disease(s) such as psychiatric and/or physical disease(s).\n4. Participants with a complication of psychiatric disorders in Axis I or personality disorder in Axis II defined in DSM-IV-TR Japanese version.\n5. Participants with organic mental disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Latency To Persistent Sleep (LPS)","description":"The objective measure, LPS, defined as the amount of time measured in minutes it takes to fall asleep was based on polysomnography (PSG) objective assessments of sleep disturbance. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":"37.8"},{"groupId":"OG001","value":"24.4","spread":"22.7"},{"groupId":"OG002","value":"20.9","spread":"24.3"},{"groupId":"OG003","value":"12.8","spread":"11.2"},{"groupId":"OG004","value":"14.3","spread":"22.6"}]}]}]},{"type":"SECONDARY","title":"Total Sleep Time (Objective & Subjective)","description":"Total sleep time defined as total sleeping time from bedtime to final awakening (measured in minutes) was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective total sleep time was based on PSG-based assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"414.0","spread":null},{"groupId":"OG001","value":"438.3","spread":null},{"groupId":"OG002","value":"452.5","spread":null},{"groupId":"OG003","value":"453.4","spread":null},{"groupId":"OG004","value":"448.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"360.0","spread":null},{"groupId":"OG001","value":"390.0","spread":null},{"groupId":"OG002","value":"397.5","spread":null},{"groupId":"OG003","value":"420.0","spread":null},{"groupId":"OG004","value":"411.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sleep Efficiency","description":"Sleep efficiency (SE) was an assessment obtained from PSG during the treatment period and was defined as the ratio of total sleep time to the total time in bed of 8 hours \\* 100, expressed as a percent.\n\nPSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the patient's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"91.3","spread":null},{"groupId":"OG002","value":"94.3","spread":null},{"groupId":"OG003","value":"94.5","spread":null},{"groupId":"OG004","value":"93.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Wake Time After Sleep Onset (WASO)- Objective & Subjective","description":"Wake Time After Sleep Onset (WASO) defined as total awakening time from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective WASO was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"22.5","spread":null},{"groupId":"OG002","value":"17.8","spread":null},{"groupId":"OG003","value":"18.8","spread":null},{"groupId":"OG004","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"37.5","spread":null},{"groupId":"OG003","value":"40.0","spread":null},{"groupId":"OG004","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Awakenings (Objective & Subjective)","description":"Number of awakenings defined as the total number of spontaneous awakenings from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective number of awakenings was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"3.5","spread":null},{"groupId":"OG003","value":"2.8","spread":null},{"groupId":"OG004","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.5","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Sleep Latency (SL)","description":"The subjective measure, SL, defined as the amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":"47.8"},{"groupId":"OG001","value":"45.5","spread":"36.7"},{"groupId":"OG002","value":"32.6","spread":"26.4"},{"groupId":"OG003","value":"28.4","spread":"23.8"},{"groupId":"OG004","value":"28.0","spread":"24.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Dysgeusia","Somnolence","Dermatitis Contact","Dizziness","Feeling Abnormal"]}}}